List of large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7070959 | REGENERON PHARMACEUTICALS, INC. | Modified chimeric polypeptides with improved pharmacokinetic properties |
Jun, 2023
(3 months ago) | |
| US10406226 | REGENERON PHARMACEUTICALS, INC. | Method of manufacturing VEGF antagonist fusion proteins |
Mar, 2026
(2 years from now) | |
| US11066458 | REGENERON PHARMACEUTICALS, INC. | VEGF antagonist formulations suitable for intravitreal administration |
Jun, 2027
(3 years from now) | |
| US10464992 | REGENERON PHARMACEUTICALS, INC. | VEGF antagonist formulations suitable for intravitreal administration |
Jun, 2027
(3 years from now) | |
| US11084865 | REGENERON PHARMACEUTICALS, INC. | VEGF antagonist formulations suitable for intravitreal administration |
Jun, 2027
(3 years from now) | |
| US10415055 | REGENERON PHARMACEUTICALS, INC. | Enhanced expression and stability regions |
Jun, 2028
(4 years from now) | |
| US9222106 | REGENERON PHARMACEUTICALS, INC. | Enhanced expression and stability regions |
Jun, 2028
(4 years from now) | |
| US9669069 | REGENERON PHARMACEUTICALS, INC. | Use of a VEGF antagonist to treat angiogenic eye disorders |
Jan, 2032
(8 years from now) | |
| US11253572 | REGENERON PHARMACEUTICALS, INC. | Use of a VEGF antagonist to treat angiogenic eye disorders |
Jan, 2032
(8 years from now) | |
| US10130681 | REGENERON PHARMACEUTICALS, INC. | Use of a VEGF antagonist to treat angiogenic eye disorders |
Jan, 2032
(8 years from now) | |
| US10888601 | REGENERON PHARMACEUTICALS, INC. | Use of a VEGF antagonist to treat angiogenic eye disorders |
Jan, 2032
(8 years from now) | |
| US10857205 | REGENERON PHARMACEUTICALS, INC. | Use of a VEGF antagonist to treat angiogenic eye disorders |
Jan, 2032
(8 years from now) | |
| US10828345 | REGENERON PHARMACEUTICALS, INC. | Use of a VEGF antagonist to treat angiogenic eye disorders |
Jan, 2032
(8 years from now) | |
| US9254338 | REGENERON PHARMACEUTICALS, INC. | Use of a VEGF antagonist to treat angiogenic eye disorders |
May, 2032
(8 years from now) | |
| US11332771 | REGENERON PHARMACEUTICALS, INC. | Serum-free cell culture medium |
Mar, 2034
(10 years from now) | |
| USD858754 | REGENERON PHARMACEUTICALS, INC. | Syringe cap |
Sep, 2034
(10 years from now) | |
| US9816110 | REGENERON PHARMACEUTICALS, INC. | CHO integration sites and uses thereof |
Oct, 2035
(12 years from now) | |
| USD906102 | REGENERON PHARMACEUTICALS, INC. | Packaging |
Dec, 2035
(12 years from now) | |
| US10927342 | REGENERON PHARMACEUTICALS, INC. | Taurine supplemented cell culture medium and methods of use |
Aug, 2036
(12 years from now) | |
| USD934069 | REGENERON PHARMACEUTICALS, INC. | Packaging |
Oct, 2036
(13 years from now) | |
| US10669594 | REGENERON PHARMACEUTICALS, INC. | Compositions and methods for detecting a biological contaminant |
Feb, 2037
(13 years from now) | |
| US10905786 | REGENERON PHARMACEUTICALS, INC. | Sterilisation method |
Mar, 2038
(14 years from now) | |
| US10918754 | REGENERON PHARMACEUTICALS, INC. | Sterilisation method |
Mar, 2038
(14 years from now) | |
| US10973879 | REGENERON PHARMACEUTICALS, INC. | Use of a VEGF antagonist to treat angiogenic eye disorders |
May, 2039
(15 years from now) | |
| US11160918 | REGENERON PHARMACEUTICALS, INC. | Medical device packaging and related methods |
Jul, 2039
(15 years from now) | |
| US11104715 | REGENERON PHARMACEUTICALS, INC. | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants |
Aug, 2040
(16 years from now) | |
| US11299532 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(16 years from now) | |
| US11174283 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(16 years from now) | |
| US11306135 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(16 years from now) | |
| US11053280 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(16 years from now) | |
| US11186625 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(16 years from now) | |
| US10857231 | REGENERON PHARMACEUTICALS, INC. | Formulations of VEG antagonist fusion proteins and method of manufacturing them | () |
Ingredients: AFLIBERCEPT
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic